Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lyell Immunopharma, Inc.LYEL · Entity 5757 | Chief Medical Officer | October 12, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lyell Immunopharma, Inc.
Report date October 12, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,857 |
Reported balance
After 2026-10-12 transaction · row 1
1 source rowRow 1 · 2026-10-12 · Sale · Disposed 422 · Balance 19,857 F1: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units. F2: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $8.54 to $8.63 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
F2: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $8.54 to $8.63 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 12, 2026 Filed Oct 13, 2026 21:17 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | SaleCommon Stock | 422 | $8.63 | $3,641.86 |
DisclosureSEC source: 0002150331-26-000003 · form4-10132026_091052.xml · nonDerivative · entry 1 Aguirre Jarrad Mattieu · CIK 0002150331 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,857 F1 · shares: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units. F2 · price: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $8.54 to $8.63 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| September 10, 2026 Filed Sep 10, 2026 23:31 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 47,500 | $0.00 Strike: $12.20 | $0.00 |
DisclosureSEC source: 0002150331-26-000002 · form4-09102026_110951.xml · derivative · entry 2 Aguirre Jarrad Mattieu · CIK 0002150331 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 47,500 shares Expires 2036-09-09 F2 · derivative.exercise_date: 12.5% of the option shares will vest on February 28, 2027, with the remaining option shares to vest in equal monthly installments over the following 42 months, subject to the reporting person providing service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.